Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Universitë De Bordeaux

UniversitÉ Paris Descartes

Institut Polytechnique De Bordeaux

Universite Paris Cité

Paris Sciences Et Lettres

Institut De Recherche Pour Le Developpement (ird)

Ecole Nationale Superieure D'arts Et Metiers

Centre National De La Recherche Scientifique-cnrs

UniversitÉ De Paris

Inserm (institut National De La Sante Et De La Recherche Medicale)

Institut De Recherche Pour Le Developpement

Ecole Nationale Superieure D'arts Et Metiers (ensam)

Inserm

Pascal Bigey

Daniel Scherman

Virginie Escriou

Francine Behar-Cohen

Pierre Tchoreloff

Philippe Deloron

Christine Charrueau

Nicaise Tuikue Ndam

Sedami Ursula Alix Carine Gnidéhou

Mickaël Quiviger

David Benezra

Carole Bloquel

Virginie Busignies-goddin

Sédami Ursula Alix Carine GNIDÉHOU

The invention relates to a process for the manufacture of a tablet comprising a nucleic acid vector.

Nucleic acid vector tablets

The invention relates to a composition including (1) an anionic macromolecule except nucleic acids, (2) a cationic lip, and (3) a nucleic acid having a size lower than or equal to 200 nucleotides, such as an interference RNA, and to the use thereof in gene therapy.

Vectors including an anionic macromolecule and a cationic lipid for delivering small nucleic acids

The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.

Vaccines against pregnancy-associated malaria

The present invention relates, generally, to improved methods of delivering a biologically active agent, in particular a therapeutic or prophylactic nucleic acid, to the ocular sphere of a subject comprising administering said agent to the ciliary body tissue(s) or cells and/or to the extra-ocular muscle tissue or cells. More particularly, the invention relates to devices, their uses, notably in gene therapy, and to methods for treating pathologies of the ocular sphere by specific ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration of a therapeutic product and transfer thereof into the ocular tissue to be treated. This invention also relates to pharmaceutical compositions comprising the product in a form suitable for ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration, their preparation and uses.

Methods and devices for delivering a therapeutic product to the ocular sphere of a subject

Growing community of inventors

Paris, France

Pascal Bigey